Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Noan-Minh Chau"'
Autor:
Ying-Hsia Chu, Huihua Li, Hui Shan Tan, Valerie Koh, Johnathan Lai, Wai Min Phyo, Yukti Choudhury, Ravindran Kanesvaran, Noan Minh Chau, Chee Keong Toh, Quan Sing Ng, Puay Hoon Tan, Balram Chowbay, Min-Han Tan
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134102 (2015)
Sunitinib is a tyrosine kinase inhibitor used as first-line treatment for metastatic renal cell carcinoma (mRCC). Asian ethnicity has been previously associated with lower clearance and greater toxicities for sunitinib treatment, relative to Caucasia
Externí odkaz:
https://doaj.org/article/cd634b220cf4462281ea4d347fd436a1
Publikováno v:
Expert Review of Anticancer Therapy. 14:271-277
Cytoreductive nephrectomy (CN) is an integral part of the treatment of patients with metastatic renal cell carcinoma. Improved survival has been shown with CN and IFN-α. The introduction of targeted therapy for metastatic renal cell carcinoma has ra
Autor:
Xiu Ping Chue, Hwee Lin Wee, Noan Minh Chau, Alexandre Chan, Min-Han Tan, Han Kiat Ho, Xue Jing Chong, Ravindran Kanesvaran, Yi Ling Teo
Publikováno v:
Cancer Chemotherapy and Pharmacology. 73:381-388
Sunitinib commonly exhibits dose-limiting dermatological toxicities (DTs) that adversely affect health-related quality of life (HRQoL). Pharmacological activity of sunitinib is attributed to sunitinib and an equipotent, active metabolite, SU12662. Th
Autor:
Rainy Umbas, Miah Hiang Tay, Edmund Chiong, Hong Gee Sim, Noan Minh Chau, Bin Tean Teh, Min-Han Tan, Santosh Kumar
Publikováno v:
The Lancet Oncology. 14:e524-e534
Summary Treatment of renal-cell carcinoma has progressed over the past decade, in terms of surgical and systemic therapy. Current treatment guidelines are based on clinical evidence, but do not take into account resource limitations among different c
Autor:
Min-Han Tan, Johnathan Lai, Balram Chowbay, Hui Shan Tan, Huihua Li, Valerie Cui Yun Koh, Ying-Hsia Chu, Puay Hoon Tan, Yukti Choudhury, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Chee Keong Toh, Wai Min Phyo
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 8, p e0134102 (2015)
PLoS ONE, Vol 10, Iss 8, p e0134102 (2015)
Sunitinib is a tyrosine kinase inhibitor used as first-line treatment for metastatic renal cell carcinoma (mRCC). Asian ethnicity has been previously associated with lower clearance and greater toxicities for sunitinib treatment, relative to Caucasia
Autor:
Min-Han Tan, Han Kiat Ho, Noan Minh Chau, Yi Ling Teo, Xiu Ping Chue, Alexandre Chan, Hwee Lin Wee, Ravindran Kanesvaran
Publikováno v:
Targeted oncology. 10(3)
An attenuated dosing (AD) regimen of 37.5 mg daily in repeated 4 week on, 2 week off cycles has been proposed to ameliorate frequent dose modifications caused by the toxicity observed with the approved dosing regimen of sunitinib for metastatic renal
Autor:
Tiffany Tang, Miah Hiang Tay, Huihua Li, Alexandre Chan, Ravindran Kanesvaran, Hui Shan Tan, Xin Yao, Quan Sing Ng, Yu Wen Hong, Gilberto Lopes, Min-Han Tan, Chee Keong Toh, Alvin Wong, Noan Minh Chau
Publikováno v:
Clinical genitourinary cancer. 13(4)
Background The use of sunitinib at conventional doses (50 mg/d, 6-week cycles: 4 weeks of treatment, then 2 weeks of no treatment) in Asian patients with metastatic renal cell carcinoma (mRCC) is associated with high real-world toxicities. Patients a
Autor:
Edmund Chiong, Miah Hiang Tay, Min Han Tan, Santosh Kumar, Hong Gee Sim, Bin Tean Teh, Rainy Umbas, Noan Minh Chau
Publikováno v:
The Lancet. Oncology. 13(11)
Treatment of renal-cell carcinoma has progressed over the past decade, in terms of surgical and systemic therapy. Current treatment guidelines are based on clinical evidence, but do not take into account resource limitations among different countries
Autor:
Mabel Wong, Jing Jin, Min Han Tan, Yee Mei Lee, Ten Eng Lee, Ying Ding, Hong Chan Yong, Siew Eng Lim, Louis YA Chai, Noan Minh Chau, Li Yang Hsu
Publikováno v:
Annals of the Academy of Medicine, Singapore. 41(7)
Introduction: Febrile neutropenia (FN) is a significant cause of mortality and morbidity in oncology and haematology units worldwide. The overall mortality in hospital surveys in Singapore surveys on post-chemotherapy FN has ranged between 3.0% and 8
Autor:
Naoto Takahashi, V. S. Nadarajan, Yijun Ruan, Anbupalam Thalamuthu, Wing-Kin Sung, Xing Yi Woo, Hae Tha Mya, Sheila Soh, Xiaoan Ruan, Wen Chun Juan, Kazutoshi Isobe, Markus M. Nöthen, Wan-Teck Lim, John W.J. Huang, Hein Than, Yao Fei, L.Y. Yang, Chia-Tien Chang, Dianne Poh, Noan-Minh Chau, Axel M. Hillmer, Liang Piu Koh, Ai Leen Ang, Gee Fung How, Mei-Kim Ang, Yeow Tee Goh, Lay Cheng Lim, Tan Min Chin, Daniel Shao-Weng Tan, Wee Joo Chng, Balram Chowbay, Audrey S.M. Teo, Hiroyuki Mano, Ju Ee Seet, Niranjan Nagarajan, Quan Sing Ng, Shenli Zhang, Pramila N. Ariyaratne, Atif Shahab, Wan Ting Poh, Manabu Soda, Patrick Tan, Yasushi Yatabe, Kenichi Sawada, Vikrant Kumar, Ross A. Soo, Tien Yin Wong, Valere Cacheux-Rataboul, Charles Chuah, Eng Huat Tan, John Carson Allen, King Pan Ng, Wah Heng Lee, S. Tiong Ong, Tun Kiat Ko
Publikováno v:
Nature medicine. 18(4)
Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-driven malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor receptor-mutated non-small-cell lung cancer (EGFR NSCLC). However, th